Molecular Evolutionary Models in Drug Discovery
- 1st Edition - January 24, 2020
- Latest edition
- Author: Juan Bueno
- Language: English
Molecular Evolutionary Models in Drug Discovery explores the application of evolutionary molecular models in drug discovery in which secondary metabolites play a fundament… Read more
Molecular Evolutionary Models in Drug Discovery explores the application of evolutionary molecular models in drug discovery in which secondary metabolites play a fundamental role. Secondary metabolites are not produced in isolation, they are the result of the interaction of genes, metabolism and the environment. The book examines the role of secondary metabolites as leads in drug discovery and on the development of a rational bioprospecting model for new medicines based on the evolution of secondary metabolism. These evolutionary models are part of biological systems and are the most reliable expression of the functioning of living beings.
- Examines the integration and application of evolutionary models in the pharmaceutical industry to create new drug development platforms
- Investigates the biotechnological prospecting of secondary metabolites and their potential use in the discovery of new drugs
- Evaluates the ecosystem of living beings and how its molecular adaptation might improve the success of therapies
Pharmaceutical scientists; pharmacologists, researchers, biologists, medical microbiologists, bioprospectors, biodiversity researchers, biochemists, pharmacists, and clinicians, and those who are interested in drug discovery; R&D of the preclinical drug development
1. Introduction2. Molecular Autopoiesis3. Natural products and molecular networks4. Symbiogenesis autopoietic5. Metabolomic autopoiesis6. Clinical outcome and autopoiesis7. Toxical autopoiesis8. Future Research and Applications
- Edition: 1
- Latest edition
- Published: January 24, 2020
- Language: English
JB
Juan Bueno
Dr. Bueno is currently the Chief Scientific Officer for the Research Center of Bioprospecting and Biotechnology for Biodiversity Foundation (BIOLABB). He has an MD from Caldas University, Manizales, Colombia (2001) and a Master degree in biomedical sciences from Antioquia University, Medellín, Colombia (2008). He is an expert in the design and implementation of antimicrobial platforms for to evaluate natural products and synthesis drugs with the aim of optimize in vitro antimicrobial activity selection of new chemical entities for future anti-infective pharmaceuticals. He was a Fellow, COLCIENCIAS-Universidad de Caldas (2002), a Fellow of University of the United Nations in antifungal susceptibility testing, Instituto Nacional de Enfermedades Infecciosas, INEI.ANLIS, Buenos Aires, Argentina (2004), and a Fellow, International Visitor Leadership Program on “Public Health”, United States Department of State, Bureau of Educational and Cultural Affairs (2012). He has been awarded by the Colombian Dermatology Association for best research in dermatology (2006), the Enrique Nuñez Olarte award for pharmacological research by the Colombian Pharmacology Association (2009). Author of 40 articles in pharmacological research. Author in seven chapter books in antimicrobial drug discovery.
Affiliations and expertise
Chief Scientific Officer, Research Center of Bioprospecting and Biotechnology for Biodiversity Foundation (BIOLABB)Read Molecular Evolutionary Models in Drug Discovery on ScienceDirect